EyePoint Pharmaceuticals has a total of 987 patents globally, out of which 536 have been granted. Of these 987 patents, more than 41% patents are active. United States of America is where EyePoint Pharmaceuticals has filed the maximum number of patents, followed by and Europe (EPO) and Japan. Parallelly, USA seems to be the main focused R&D centre and also is the origin country of EyePoint Pharmaceuticals.
EyePoint Pharmaceuticals develops treatments for serious eye diseases, using their proprietary Durasert technology for long-lasting drug delivery in the eye. EyePoint Pharmaceuticals, founded in 1987 as pSivida Corp, is headquartered in Watertown, Massachusetts (USA).
Do read about some of the most popular patents of EyePoint Pharmaceuticals which have been covered by us in this article and also you can find EyePoint Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over EyePoint Pharmaceuticals patent portfolio.
How many patents does EyePoint Pharmaceuticals have?
EyePoint Pharmaceuticals has a total of 987 patents globally. These patents belong to 106 unique patent families. Out of 987 patents, 407 patents are active.
How Many Patents did EyePoint Pharmaceuticals File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | EyePoint Pharmaceuticals Applications Filed | EyePoint Pharmaceuticals Patents Granted |
| 2024 | 8 | 32 |
| 2023 | 54 | 47 |
| 2022 | 51 | 24 |
| 2021 | 42 | 26 |
| 2020 | 40 | 37 |
| 2019 | 31 | 40 |
| 2018 | 26 | 23 |
| 2017 | 19 | 26 |
| 2016 | 40 | 28 |
| 2015 | 27 | 17 |
How many EyePoint Pharmaceuticals patents are Alive/Dead?
How Many Patents did EyePoint Pharmaceuticals File in Different Countries?
Countries in which EyePoint Pharmaceuticals Filed Patents
| Country | Patents |
| United States of America | 203 |
| Europe (EPO) | 95 |
| Japan | 93 |
| Australia | 75 |
| China | 63 |
| Canada | 51 |
| Hong Kong (S.A.R.) | 47 |
| Germany | 28 |
| New Zealand | 28 |
| United Kingdom | 24 |
| India | 23 |
| Taiwan | 20 |
| Austria | 19 |
| Spain | 18 |
| Korea (South) | 17 |
| Mexico | 15 |
| Macao | 13 |
| Singapore | 13 |
| Brazil | 10 |
| Argentina | 8 |
| Denmark | 6 |
| Israel | 5 |
| Russian Federation | 5 |
| Slovenia | 4 |
| Norway | 4 |
| Portugal | 4 |
| Serbia | 4 |
| Slovakia | 3 |
| Lithuania | 3 |
| Hungary | 3 |
| Croatia | 3 |
| Cyprus | 3 |
| Poland | 3 |
| Estonia | 3 |
| Italy | 3 |
| Albania | 3 |
| Malta | 3 |
| Indonesia | 1 |
| Ukraine | 1 |
| Malaysia | 1 |
| Former Yugoslav Republic of Macedonia | 1 |
| Montenegro | 1 |
| United Arab Emirates | 1 |
| Czech Republic | 1 |
| South Africa | 1 |
Where are Research Centres of EyePoint Pharmaceuticals Patents Located?
10 Best EyePoint Pharmaceuticals Patents
US20040208910A1 is the most popular patent in the EyePoint Pharmaceuticals portfolio. It has received 210 citations so far from companies like Allergan, Evonik, and Minipumps.
Below is the list of 10 most cited patents of EyePoint Pharmaceuticals:
| Publication Number | Citation Count |
| US20040208910A1 | 210 |
| US20040009222A1 | 188 |
| US20040221855A1 | 170 |
| US6852106B2 | 160 |
| US20070255198A1 | 145 |
| US20040022853A1 | 139 |
| US20040175410A1 | 139 |
| US6770480B1 | 124 |
| US7332339B2 | 113 |
| US6936270B2 | 101 |
What are EyePoint Pharmaceuticals key innovation segments?
What Technologies are Covered by EyePoint Pharmaceuticals?
The chart below distributes patents filed by EyePoint Pharmaceuticals in different countries on the basis of the technology protected in patents. It also represents the markets where Ophthalmic Sciences thinks it’s important to protect particular technology inventions.
R&D Focus: How has EyePoint Pharmaceuticals search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by EyePoint Pharmaceuticals?